Education
About Us
Working with TipRanks
Follow Us
Inventiva SA (FR:IVA)
:IVA
Top Page
Inventiva
(LSE:IVA)
Rating:45Neutral
Price Target:
€2.50
▼(-9.42%Downside)
Inventiva (IVA) vs. iShares MSCI France ETF (EWQ)
Market Cap
€383.58M
Dividend YieldN/A
Average Volume (3M)30.10K
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue Growth-47.37%
EPS Growth-26.56%
CountryFR
Employees114
SectorHealthcare
Sector Strength40
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.68
Shares Outstanding139,151,280
10 Day Avg. Volume33,484
30 Day Avg. Volume30,097
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.75
Price to Sales (P/S)0.00
P/FCF Ratio-10.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.00Price Target Upside262.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Inventiva Business Overview & Revenue Model
Company DescriptionInventiva (IVA) is a clinical-stage biopharmaceutical company specializing in the research and development of oral small molecule therapies aimed at treating patients with non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases with significant unmet medical needs. The company leverages its deep expertise in transcription factors, epigenetics, and nuclear receptors to develop innovative treatments designed to improve patient outcomes.
How the Company Makes MoneyInventiva primarily generates revenue through strategic collaborations, licensing agreements, and research partnerships with pharmaceutical companies. These arrangements often involve upfront payments, milestone payments contingent on the achievement of specific development or regulatory goals, and royalties on sales of successfully commercialized products. Additionally, the company's pipeline of product candidates provides future revenue potential upon successful commercialization. Significant partnerships can provide financial support and resources, enhancing Inventiva's ability to advance its drug candidates through clinical development.
Inventiva Earnings Call Summary
Earnings Call Date:Mar 26, 2025
(Q4-2024)
| % Change Since: 0.36%|
Next Earnings Date:Sep 25, 2025
Earnings Call Sentiment Positive
The earnings call presented a largely positive outlook with significant progress in clinical trials, financial performance, and strategic global partnerships. However, challenges included workforce reductions and a significant increase in net loss. The highlights of strategic advancements and robust cash position outweigh the lowlights.Q4-2024 Updates
Positive Updates
Progress in Clinical Development of lanifibranor
Completed screening for Phase 3 NATiV3 trial with positive recommendations from data monitoring committees, indicating no modifications are necessary. The trial is on track for completion of recruitment in H1 2025 and topline results expected in H2 2026.
Positive Financial Performance
Inventiva raised $184 million in 2024 through dilutive and non-dilutive financing operations, significantly increasing cash position to €96.6 million from €36 million in 2023.
Strategic Partnerships and Global Expansion
Launched clinical development of lanifibranor in Japan with partner Hepalys and secured licensing agreements in South Korea and China, positioning lanifibranor as a leading oral drug in MASH for these regions.
Strong Governance and Leadership Team
Reinforced Board of Directors with experienced members from the biotech industry, including Andre Turenne and Mark Pruzanski, to drive commercialization and strategic growth.
Strengthened Clinical Data Set
Published positive results from LEGEND trial showing significant reduction in HBA1C and improvement in insulin sensitivity with lanifibranor, particularly when combined with empagliflozin.
Negative Updates
Workforce Reduction
Decision to focus resources on lanifibranor led to the cessation of all pre-clinical activities not related to it, resulting in a reduction of approximately 50% of the workforce.
Revenue Decline
Revenues decreased to €9.2 million in 2024 compared to €17.5 million in 2023, primarily due to lower milestone payments.
Increased Net Loss
Net loss for 2024 increased to €184.2 million from €110.4 million in 2023, due to various factors including non-cash financial adjustments.
Company Guidance
During the conference call, Inventiva provided guidance on several key metrics and strategic initiatives for the fiscal year 2024. The company reported a cash position of €96.6 million at the end of 2024, compared to €36 million at the end of 2023, primarily due to successful financing operations totaling approximately $184 million. Inventiva anticipates completing the randomization of its Phase 3 NATiV3 trial for lanifibranor by the first half of 2025, with topline results expected in the second half of 2026. The company aims to utilize its strengthened financial position to prepare for regulatory filings and potential commercialization, having already reinforced its board and development team. Despite a net loss of €184.2 million in 2024, Inventiva remains focused on advancing lanifibranor, benefiting from positive trial data and strategic partnerships in Asia, with a cash runway extending to September 2025, or potentially to September 2026 with additional financing.Inventiva Financial Statement Overview
Summary
Inventiva faces considerable financial challenges, with declining revenues, persistent losses, and high leverage. The balance sheet shows negative equity, raising concerns about long-term sustainability. While the company has managed to secure financing, the reliance on external capital and negative cash flows highlight the need for strategic improvements to stabilize and grow the business.Income Statement
Inventiva's income statement shows a concerning trajectory with declining revenues from 2023 to 2024 and persistent negative net income, indicating operational challenges. The gross profit margin is consistently high, as expected for the industry, but the negative net profit margin and EBIT margin highlight significant profitability issues. The company's revenue growth has turned negative, suggesting difficulties in sustaining sales momentum.40
Negative
Balance Sheet
The balance sheet reflects financial instability with negative stockholders' equity, indicating that liabilities exceed assets. The increasing debt-to-equity ratio is a major concern, suggesting high financial leverage and potential solvency risks. Despite these challenges, the company has maintained a consistent level of cash and short-term investments, which could provide some liquidity buffer.30
Negative
Cash Flow
Cash flow analysis reveals significant negative operating cash flow, indicating that the company is not generating sufficient cash from its core operations. The free cash flow is also negative, which could impact future investments and growth. However, the high financing cash flow in recent years suggests reliance on external funding to sustain operations.45
Neutral
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.72M | 17.48M | 12.18M | 4.19M | 372.00K |
| Gross Profit | 9.20M | 17.50M | 11.18M | 3.18M | -474.00K |
| EBITDA | -96.69M | -102.04M | -57.11M | -52.27M | -31.77M |
| Net Income | -184.21M | -110.43M | -54.27M | -49.64M | -31.62M |
Balance Sheet | |||||
| Total Assets | 118.97M | 69.56M | 116.00M | 121.98M | 138.92M |
| Cash, Cash Equivalents and Short-Term Investments | 96.56M | 26.99M | 87.78M | 95.38M | 113.02M |
| Total Debt | 54.33M | 37.49M | 34.51M | 10.12M | 13.25M |
| Total Liabilities | 225.61M | 101.59M | 70.53M | 33.12M | 27.71M |
| Stockholders Equity | -106.65M | -32.03M | 45.48M | 88.87M | 111.21M |
Cash Flow | |||||
| Free Cash Flow | -86.26M | -82.15M | -45.49M | -48.16M | -30.88M |
| Operating Cash Flow | -85.93M | -81.61M | -44.93M | -47.63M | -30.59M |
| Investing Cash Flow | 8.74M | -7.73M | 8.87M | -1.79M | -8.56M |
| Financing Cash Flow | 145.59M | 29.08M | 37.27M | 25.45M | 111.67M |
Inventiva Technical Analysis
Positive
2.76
Price Trends
2.85
Negative
2.85
Negative
2.56
Positive
Market Momentum
-0.03
Negative
50.26
Neutral
57.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:IVA, the sentiment is Positive. The current price of 2.76 is above the 20-day moving average (MA) of 2.71, below the 50-day MA of 2.85, and above the 200-day MA of 2.56, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 57.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:IVA.
Inventiva Peers Comparison
Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | €502.62M | ― | -148.98% | ― | ― | 18.52% | |
55 Neutral | €4.61B | 17.01 | -50.16% | 3.67% | 15.32% | -9.52% | |
54 Neutral | $170.55M | 107.11 | 2.17% | ― | 134.56% | ― | |
51 Neutral | €473.46M | ― | -44.11% | ― | 21.64% | -196.47% | |
50 Neutral | €231.84M | ― | -199.50% | ― | ― | -40.10% | |
45 Neutral | €383.58M | ― | ― | -47.37% | -26.56% |
* Healthcare Sector Average
Performance Comparison
FR:IVA
Inventiva
2.76
0.26
10.40%
FR:ABVX
Abivax SA
8.41
-3.81
-31.18%
FR:GNFT
Genfit
3.37
-0.82
-19.57%
FR:VLA
Valneva
2.75
-0.73
-21.00%
FR:DBV
DBV Technologies
1.65
0.85
106.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.